Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Davis Polk Advises Accuray Incorporated on Its Private Exchange Offer
Davis Polk advised Accuray Incorporated in connection with a private exchange of approximately $47 million aggregate…
$3.1 Billion Financing for inVentiv’s Merger with INC Research
Davis Polk advised the administrative agent in connection with a $3.1 billion best-efforts financing comprised of a $1…
Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company…
Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of…
LabCorp Acquires Chiltern
Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to LabCorp in connection with its approximately $1.2…
Biotoscana Investments $377.7 Million Initial Public Offering
Davis Polk advised Biotoscana Investments S.A. and the selling shareholders in connection with an initial public offering of…
Davis Polk Advises Pernix Therapeutics Holdings, Inc. on Its Refinancing Transactions
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with a series of refinancing transactions that are…
Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public…
Davis Polk Advises Mitsubishi Tanabe Pharma on Its Acquisition of NeuroDerm
Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd…
Akcea Therapeutics Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of…